Anthropic develops AI models, including Claude 3.5 Sonnet, that prioritize safety in large-scale AI systems through techniques like Constitutional AI, which ensures harmlessness via AI feedback. The company addresses the risks associated with deploying advanced AI technologies by creating reliable and beneficial systems for enterprises.

Manifest Technologies develops individualized brain therapeutics using its NAIO™ platform, which integrates and analyzes complex, multi-modal neuroimaging data sets. This AI-powered computational neuroimaging system quantifies neural and symptom data to personalize therapy selection for CNS disorders. The platform supports pharmaceutical CNS R&D through applications in biomarker discovery, target validation, and patient stratification for clinical trials.

Paradromics is developing a high data-rate brain-computer interface (BCI) that directly accesses individual neural signals to enable communication for individuals with severe motor impairments. The Connexus Direct Data Interface translates neural activity into synthesized speech and cursor control, facilitating social connection and restoring independence for users.

Science is a clinical-stage technology company developing biohybrid neural interfaces and advanced neural recording electronics to address serious unmet medical needs in neuroscience. Their technologies aim to enhance neural communication and restore vision, facilitating new treatment possibilities for patients with neurological disorders.

Synchron develops a brain-computer interface (BCI) designed to allow individuals to control digital devices using thought alone. This neurotechnology is implanted via a minimally-invasive endovascular procedure, avoiding open brain surgery. The platform aims to restore autonomy and enhance social connection for users with physical limitations.